Lantheus Holdings, INC 8-K filings

Lantheus Holdings, Inc. announced its second quarter 2026 financial results and a definitive agreement to be acquired by Curium US Holdings LLC for up to $8.0 billion.

Curium and Lantheus Holdings, Inc. have entered into a definitive agreement for Curium to acquire Lantheus in a cash and stock deal valued at up to $8 billion.

Lantheus Holdings announced first quarter 2026 financial results, with worldwide revenue reaching $377.3 million, while also receiving FDA approvals for key products.

Lantheus Holdings shareholders approved the 2026 Equity Incentive Plan and a board declassification amendment at the 2026 Annual Meeting.

Lantheus Holdings, Inc. announced its fourth quarter and full year 2025 financial results, revealing a strategic pivot towards innovative radiodiagnostics and lower 2026 guidance.

Lantheus Holdings, Inc. details CEO Brian Markison's retirement plan, including a consulting agreement and separation terms.

Lantheus Holdings reported mixed third-quarter 2025 financial results, including a significant drop in GAAP earnings, alongside a major leadership transition with CEO Brian Markison's retirement and the appointment of Mary Anne Heino as Executive Chair and Interim CEO.

Lantheus Holdings, Inc. announced that Chief Commercial Officer Amanda Morgan is taking a leave of absence for personal reasons, effective August 8, 2025.

Lantheus Holdings, Inc. reported a decline in second-quarter revenue and adjusted earnings per share, leading to a significant reduction in its full-year 2025 financial guidance, despite strategic acquisitions and a new share repurchase program.

Lantheus Holdings, Inc. successfully completed its previously announced acquisition of Life Molecular Imaging Ltd. for $350 million and appointed Dr. Ludger Dinkelborg as its new Head of Research and Development.

Lantheus Holdings announces its Q1 2025 financial results, highlighting revenue growth, earnings decline, strategic acquisitions, and a planned divestiture.

Lantheus Holdings, Inc. amended and restated its bylaws and conducted its annual meeting of stockholders on May 1, 2025, addressing various corporate governance matters.

Lantheus Holdings completes its acquisition of Evergreen Theragnostics, enhancing its radiopharmaceutical capabilities and pipeline.

Lantheus Holdings announces strong fourth quarter and full-year 2024 results, highlighted by PYLARIFY achieving blockbuster status and strategic acquisitions to diversify its portfolio.

Lantheus Holdings has appointed Dr. Phuong Khanh Morrow, a pharmaceutical executive with oncology expertise, to its Board of Directors, increasing the board size to eleven members.

Lantheus Holdings, Inc. has agreed to acquire Evergreen Theragnostics, Inc. for an upfront payment of $250 million in cash, plus up to $752.5 million in potential milestone payments, to enhance its radiopharmaceutical capabilities.

Lantheus Holdings will acquire Life Molecular Imaging for $350 million upfront plus potential earn-outs, enhancing its presence in the Alzheimer's disease radiodiagnostic market.

Lantheus Holdings has amended its credit agreement, increasing its revolving line of credit to $750 million and extending the maturity date to December 2029.

Lantheus Holdings, Inc. has announced the departure of its Chief Medical Officer, Jeff Humphrey, MD, effective January 3, 2025.

Lantheus Holdings has authorized a program to repurchase up to $250 million of its common stock over the next twelve months.

Lantheus Holdings announced a robust third quarter with an 18.4% revenue increase and narrowed its full-year guidance towards the higher end.

Lantheus Holdings expects to release data from its Phase 3 SPLASH trial for PNT2002 in October 2024, based on reaching 75% of the protocol-specified overall survival events.

Lantheus Holdings has appointed Julie Eastland, a seasoned biotechnology and financial executive, to its Board of Directors, effective September 3, 2024.

Lantheus Holdings announced a 22.5% increase in worldwide revenue for the second quarter of 2024, driven by strong sales of PYLARIFY and DEFINITY, while also completing three strategic acquisitions to bolster its pipeline.

Lantheus Holdings has acquired global rights to Life Molecular Imaging's RM2, a radiotheranostic pair targeting the gastrin-releasing peptide receptor (GRPR), for an upfront payment of $35 million plus potential milestones and royalties.

Lantheus Holdings has appointed Kimberly Brown as its new Chief Accounting Officer, effective July 1, 2024, with her taking over as principal accounting officer on August 1, 2024.

Lantheus Holdings has appointed a new Chief Medical Officer and Chief Science Officer, effective May 28, 2024, to accelerate innovation in radiopharmaceuticals.

Lantheus Holdings announced a 23% increase in worldwide revenue for the first quarter of 2024, driven by strong sales of PYLARIFY and DEFINITY, and raised its full-year revenue and earnings guidance.

Lantheus Holdings has increased the number of shares reserved for issuance under its 2015 Equity Incentive Plan by 4,000,000 shares, following approval at the Annual Meeting of Stockholders.

Lantheus Holdings announced strong financial results for the fourth quarter and full year 2023, with significant increases in revenue and earnings, and provided optimistic guidance for 2024.